两亲聚合物偶联佐剂与抗原共递送及佐剂组合增强抗衣原体黏膜感染疫苗保护
本研究以衣原体鼠生物型(Cm)天然MOMP(nMOMP)为抗原,用A8-35两亲聚合物包载并共价偶联EP67肽,联合Montanide ISA 720与CpG-1826佐剂,经黏膜和系统途径免疫BALB/c小鼠,以鼻内活Cm攻击后体重、肺重和肺IFU评价保护。结果显示EP67共价偶联优于游离EP67,三联佐剂组合可拓宽并增强Th1偏向的细胞与体液免疫,攻击后10天保护力与活Cm免疫相当。
要点
- EP67共价偶联至包载nMOMP的A8-35可提升保护,优于游离EP67。
- Montanide增强Th2应答并改善保护,CpG-1826进一步转向Th1。
- EP67+Montanide+CpG-1826联合攻击后10天保护与活Cm免疫相当。
核心结论
- 将EP67共价偶联到用于保持nMOMP水溶性的A8-35上,比游离EP67提供更好的保护。
- 含EP67+Montanide+CpG-1826的佐剂组合通过拓宽并增强细胞与体液免疫,进一步增强保护。
研究设计与样本
- 以A8-35两亲聚合物包载Cm天然MOMP(nMOMP),并共价偶联EP67肽。
- 佐剂包括EP67(偶联或游离)、Montanide ISA 720和CpG-1826。
- BALB/c小鼠经黏膜和系统途径免疫,以鼻内活Cm攻击作为阳性对照,并设三个阴性对照。
- 以体重变化、肺重和肺组织Cm包涵体形成单位(IFU)数评价保护。
主要发现
- 结构实验显示A8-35共价修饰后nMOMP二级结构与热稳定性保持。
- nMOMP/EP67-A8-35免疫小鼠保护优于nMOMP/A8-35+EP67组。
- 加入Montanide增强Th2应答并改善保护。
- 加入CpG-1826使免疫应答进一步拓宽、增强并偏向Th1。
- nMOMP加三种佐剂递送后,攻击后10天保护(体重、肺重、肺IFU)与活Cm免疫相当。
临床怎么用
- 提示疫苗设计中将佐剂与抗原经两亲聚合物共价共递送可能优于游离佐剂混合。
- 多佐剂组合可同时增强体液与细胞免疫,为黏膜疫苗佐剂策略提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chlamydial infections are spread worldwide and a vaccine is needed to control this pathogen. The goals of this study were to determine if the delivery of an adjuvant associated to the antigen, via a derivatized amphipol, and adjuvant combinations improve vaccine protection. METHODS: A novel approach, trapping the Chlamydia muridarum (Cm) native MOMP (nMOMP) with amphipols (A8-35), bearing a covalently conjugated peptide (EP67), was used. Adjuvants incorporated were: EP67 either conjugated to A8-35, which was used to trap nMOMP (nMOMP/EP67-A8-35), or free as a control, added to nMOMP/A8-35 complexes (nMOMP/A8-35+EP67); Montanide ISA 720 to enhance humoral responses, and CpG-1826 to elicit robust cell-mediated immunity (CMI). BALB/c mice were immunized by mucosal and systemic routes. Intranasal immunization with live Cm was used as positive control and three negative controls were included. Mice were challenged intranasally with Cm and changes in body weight, lungs weight and number of Cm-inclusion forming units (IFU) recovered from the lungs were evaluated to establish protection. To assess local responses levels of IFN- γ and Cm-specific IgA were determined in lungs' supernatants. RESULTS: Structural assays demonstrated that nMOMP secondary structure and thermal stability were maintained when A8-35 was covalently modified. Mice vaccinated with nMOMP/EP67-A8-35 were better protected than animals immunized with nMOMP/A8-35+EP67. Addition of Montanide enhanced Th2 responses and improved protection. Including CpG-1826 further broadened, intensified and switched to Th1-biased immune responses. With delivery of nMOMP and the three adjuvants, as determined by changes in body weight, lungs weight and number of IFU recovered from lungs, protection at 10 days post-challenge was equivalent to that induced by immunization with live Cm. CONCLUSIONS: Covalent association of EP67 to A8-35, used to keep nMOMP water-soluble, improves protection over that conferred by free EP67. Adjuvant combinations including EP67+Montanide+CpG-1826, by broadening and intensifying cellular and humoral immune responses, further enhanced protection.
引用
- Tifrea DF, Pal S, Le Bon C, et al. Co-delivery of amphipol-conjugated adjuvant with antigen, and adjuvant combinations, enhance immune protection elicited by a membrane protein-based vaccine against a mucosal challenge with Chlamydia. Vaccine. 2018. PMID: 30293763. doi:10.1016/j.vaccine.2018.09.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。